NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-CA-19-012 from the NIH Guide for Grants and Contracts
Notice NOT-AG-18-046 from the NIH Guide for Grants and Contracts
Notice NOT-AG-18-047 from the NIH Guide for Grants and Contracts
Funding Opportunity PA-19-074 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to stimulate clinical research that examines the role of telomeres in wellness and disease, and to advance the incorporation of telomere studies into biobehavioral programs of research. A body of research has demonstrated the contribution of telomeres to health-related outcomes; however, additional studies are needed to achieve the full potential for incorporating telomere-guided approaches for maintaining wellness, reducing the risk and burden of disease, and for advancing symptom and self-management strategies.
Funding Opportunity PA-19-073 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to stimulate clinical research that examines the role of telomeres in wellness and disease, and to advance the incorporation of telomere studies into biobehavioral programs of research. A body of research has demonstrated the contribution of telomeres to health-related outcomes; however, additional studies are needed to achieve the full potential for incorporating telomere-guided approaches for maintaining wellness, reducing the risk and burden of disease, and for advancing symptom and self-management strategies.
Notice NOT-OD-19-033 from the NIH Guide for Grants and Contracts
Notice NOT-MH-18-077 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-19-072 from the NIH Guide for Grants and Contracts. The National Library of Medicine seeks applications for novel informatics and data science approaches that can help individuals gather, manage and use data and information about their personal health. A goal of this program is to advance research and application by patients and the research community through broadly sharing the results via publication, and through open source mechanisms for data or resource sharing.
Notice NOT-AT-19-013 from the NIH Guide for Grants and Contracts
Notice NOT-DK-19-006 from the NIH Guide for Grants and Contracts
Notice NOT-MH-18-076 from the NIH Guide for Grants and Contracts
Notice NOT-EY-19-004 from the NIH Guide for Grants and Contracts
Notice NOT-EY-19-005 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-19-069 from the NIH Guide for Grants and Contracts. REISSUE of PAR-18-733 The NIH Common Fund has established the Gabriella Miller Kids First Pediatric Research Program (Kids First) to develop a pediatric research data resource populated by genome sequence and phenotype data that will be of high value for the communities of investigators who study the genetics of childhood cancers and/or structural birth defects. The overall goal of the Gabriella Miller Kids First Pediatric Data Resource is to help researchers understand the underlying mechanisms of these conditions, leading to more refined diagnostic capabilities and ultimately more targeted therapies, as well as to develop an integrated pediatric research data resource by obtaining and aggregating genome sequence and phenotype data for as many relevant structural birth defects and pediatric cancer cohorts as possible and to advance research in this area through the broad sharing of these data with the research community. This FOA is intended to promote meritorious small research projects focused on the development and analyses of childhood cancer and/or structural birth defects datasets that are part of the Kids First Data Resource or could be included in the Kids First Data Resource. Development of statistical methodology appropriate for analyzing genome-wide data relevant to childhood cancer and/or structural birth defects may also be proposed.
Notice NOT-OD-19-034 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-19-070 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite applications proposing research on current topics in Alzheimer's disease and its related dementias. Further information on the high-priority topics of interest will be announced through a series of Notices published subsequent to this FOA.
Funding Opportunity PAR-19-071 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite applications proposing new tests, animal models, techniques, etc. to advance research on Alzheimer's disease and its related dementias and which need additional preliminary data with broader dissemination to establish them for more general use in this research field. The priority topics will be announced through a series of Notices published subsequent to this FOA.
Funding Opportunity RFA-AA-19-005 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite cooperative agreement applications for research that advances promising compounds thorough the drug development pipeline for the treatment of Alcohol Use Disorder (AUD). NIAAA is seeking applications for medications development research projects from both for-profit and not-for-profit entities, including academic institutions, pharmaceutical and biotechnology companies, private and public foundations, small businesses not eligible for the SBIR/STTR program and single entities able to demonstrate significant resource commitment to the proposed project. A resource commitment from a single entity could, for example, consist of salary support for key personnel or production and formulation of clinical trial material. The aim of this FOA is to move candidate compounds through Investigational New Drug (IND) requirements, Phase 1 human safety, tolerability, and dosing studies, and Phase 2 human laboratory and proof-of-concept trials. Within these phases of drug development, each proposed project should have a defined entry and exit point. Finally, this FOA will not support animal studies to prove efficacy of the candidate compound unless required by the Food and Drug Administration or peer review. Applicants are strongly encouraged to contact the NIAAA Division of Medications Development Staff prior to submitting to this FOA.
Notice NOT-DA-19-010 from the NIH Guide for Grants and Contracts
Notice NOT-DA-19-009 from the NIH Guide for Grants and Contracts